Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress.
Oxidative stress with reactive oxygen species generation is a key weapon in the arsenal of the immune system for fighting invading pathogens and initiating tissue repair. If excessive or unresolved, however, immune-related oxidative stress can initiate further increasing levels of oxidative stress that cause organ damage and dysfunction. Targeting oxidative stress in various diseases therapeutically has proven more problematic than first anticipated given the complexities and perversity of both the underlying disease and the immune response. However, growing evidence suggests that the endocannabinoid system, which includes the CB₁ and CB₂ G-protein-coupled receptors and their endogenous lipid ligands, may be an area that is ripe for therapeutic exploitation. In this context, the related nonpsychotropic cannabinoid cannabidiol, which may interact with the endocannabinoid system but has actions that are distinct, offers promise as a prototype for anti-inflammatory drug development. This review discusses recent studies suggesting that cannabidiol may have utility in treating a number of human diseases and disorders now known to involve activation of the immune system and associated oxidative stress, as a contributor to their etiology and progression. These include rheumatoid arthritis, types 1 and 2 diabetes, atherosclerosis, Alzheimer disease, hypertension, the metabolic syndrome, ischemia-reperfusion injury, depression, and neuropathic pain.
Department of Pharmacology and Toxicology, School of Medicine, and Center for Excellence in Cardiovascular-Renal Research, University of Mississippi Medical Center, Jackson, MS 39216, USA. gbooz@umc.edu
George W
GW
Booz
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000503:physiopathology; D050197:Atherosclerosis / Q000188:drug therapy* / Q000503:physiopathology; D002185:Cannabidiol / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D063385:Cannabinoid Receptor Modulators / Q000737:chemistry / Q000378:metabolism; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007109:Immunity / Q000187:drug effects; D007249:Inflammation; D058990:Molecular Targeted Therapy / Q000639:trends; D009437:Neuralgia / Q000188:drug therapy* / Q000503:physiopathology; D018384:Oxidative Stress / Q000187:drug effects; D015427:Reperfusion Injury / Q000188:drug therapy* / Q000503:physiopathology
D000893:Anti-Inflammatory Agents; D063385:Cannabinoid Receptor Modulators; D002185:Cannabidiol
J Neurochem. 2007 Sep;102(5):1488-1496
17437545
Int Immunopharmacol. 2008 May;8(5):732-40
18387516
Immunobiology. 2010 Aug;215(8):588-97
20153077
Neurosci Lett. 2006 May 15;399(1-2):91-5
16490313
Mol Pain. 2010 Mar 17;6:16
20236533
FEBS J. 2009 Oct;276(20):5747-54
19754872
BMC Neurosci. 2010 Mar 26;11:44
20346144
Glia. 2010 Jun;58(8):889-900
20155817
Drug Metab Dispos. 2009 Aug;37(8):1733-7
19406952
Lancet Neurol. 2010 Aug;9(8):807-19
20650402
J Neural Transm (Vienna). 2010 Aug;117(8):949-60
20552234
Br J Pharmacol. 2008 Jul;154(5):1001-8
18469842
Biol Pharm Bull. 2009 Sep;32(9):1538-44
19721229
Trends Pharmacol Sci. 2009 Oct;30(10):515-27
19729208
Pharmacol Biochem Behav. 2010 Jun;95(4):375-82
20347862
J Psychopharmacol. 2009 Nov;23(8):979-83
18801821
Curr Pharm Des. 2008;14(23):2299-3305
18781980
Toxicol Appl Pharmacol. 2008 Feb 1;226(3):260-70
17950393
Mol Pharmacol. 2006 Sep;70(3):897-908
16754784
Circulation. 2010 Apr 27;121(16):1868-77
20179252
Cardiovasc Res. 2009 Dec 1;84(3):378-86
19596672
Cardiovasc Res. 2009 Mar 1;81(4):805-13
19074161
J Pharmacol Exp Ther. 2005 Aug;314(2):780-8
15878999
J Am Coll Cardiol. 2010 Dec 14;56(25):2115-25
21144973
Pharmacol Res. 2009 Aug;60(2):99-106
19569260
Neuropharmacology. 2008 Jan;54(1):244-9
17714746
CNS Neurosci Ther. 2009 Winter;15(1):65-75
19228180
Br J Pharmacol. 2008 Jan;153(2):199-215
17828291
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14851-6
20679217
Circ Res. 2010 May 28;106(10):1559-69
20508200
Int J Dev Neurosci. 2006 Apr-May;24(2-3):167-76
16472958
J Mol Cell Cardiol. 2009 May;46(5):612-20
19162037
Front Biosci (Landmark Ed). 2009 Jan 01;14:944-57
19273110
Rejuvenation Res. 2010 Apr-Jun;13(2-3):301-13
20462385
Mediators Inflamm. 2010;2010:219583
20508742
Br J Pharmacol. 2007 Aug;151(8):1272-9
17592514
Immunobiology. 2010 Aug;215(8):611-6
19833407
Autoimmunity. 2006 Mar;39(2):143-51
16698671
Chem Biodivers. 2007 Aug;4(8):1678-92
17712814
Cardiovasc Res. 2009 Dec 1;84(3):341-2
19819883
J Pharmacol Exp Ther. 2009 Mar;328(3):708-14
19074681
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Apr 29;35(3):760-8
20600462
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Apr 29;35(3):676-92
20471444
Trends Endocrinol Metab. 2010 Feb;21(2):83-8
19854062
Proc Natl Acad Sci U S A. 2006 May 16;103(20):7895-900
16672367
Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9561-6
10920191
Br J Pharmacol. 2010 Jan;159(1):122-8
20002102
Mol Vis. 2008;14:2190-203
19052649
Braz J Psychiatry. 2008 Sep;30(3):271-80
18833429
Semin Immunopathol. 2009 Jun;31(1):63-77
19357846
J Biol Chem. 2010 Jan 15;285(3):1616-26
19910459
J Leukoc Biol. 2010 Jul;88(1):33-9
20360405
Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H610-9
17384130
Toxicol Appl Pharmacol. 2010 Aug 1;246(3):141-7
20471992
Exp Eye Res. 2009 Nov;89(5):774-81
19635478
Cardiovasc Res. 2010 Mar 1;85(4):773-84
19942623
J Neuroimmune Pharmacol. 2010 Mar;5(1):103-21
19847654
Neurobiol Aging. 2012 Jan;33(1):195.e1-12
20580465
J Pharmacol Exp Ther. 2000 Jun;293(3):807-12
10869379
Circ Res. 2010 Jul 23;107(2):263-70
20558826
J Psychopharmacol. 2011 Feb;25(2):274-80
19939866
J Lipid Res. 2010 Aug;51(8):2181-90
20305287
J Physiol Pharmacol. 2009 Oct;60 Suppl 3:99-103
19996489
Mol Vis. 2010 Aug 04;16:1487-95
20806080
Trends Immunol. 2009 Jun;30(6):263-70
19427267
J Neuroimmunol. 2009 Feb 15;207(1-2):75-82
19167098
Clin Chem Lab Med. 2010 Aug;48(8):1063-73
20441482
Brain Res Rev. 2010 May;63(1-2):189-211
19944719
Am J Pathol. 2006 Jan;168(1):235-44
16400026
Mol Pharmacol. 2008 Feb;73(2):441-50
17965195
Nature. 2006 Apr 13;440(7086):944-8
16612386
Br J Pharmacol. 2010 Jun;160(3):688-700
20590572
Pharmacol Biochem Behav. 2010 Jun;95(4):434-42
20332000
Am J Physiol Heart Circ Physiol. 2007 Dec;293(6):H3602-7
17890433
J Periodontol. 2007 Sep;78(9):1788-94
17760550
Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5526-31
18641283
Int Immunopharmacol. 2009 Feb;9(2):216-22
19070683
J Neurochem. 2010 Jul;114(2):576-86
20456016
Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2210-8
17660390
Free Radic Biol Med. 2010 Feb 1;48(3):457-67
19969072
Eur J Pharmacol. 2009 Jun 10;612(1-3):61-8
19285060
Neurotherapeutics. 2009 Oct;6(4):713-37
19789075
Curr Opin Pharmacol. 2010 Apr;10(2):203-7
20167535
J Neurochem. 2004 Apr;89(1):134-41
15030397
Physiol Rev. 2007 Jan;87(1):315-424
17237348
Curr Opin Pharmacol. 2009 Apr;9(2):109-18
19230773
Am J Physiol Regul Integr Comp Physiol. 2010 Apr;298(4):R1136-42
20147611
J Neurosci. 2003 Feb 15;23(4):1398-405
12598628
Ann N Y Acad Sci. 2000;899:274-82
10863546
Am J Physiol Heart Circ Physiol. 2009 Jan;296(1):H1-12
19011041
Mediators Inflamm. 2010;2010:
20706689
Rheumatology (Oxford). 2006 Jan;45(1):50-2
16282192
Brain Res. 2007 Feb 23;1134(1):162-70
17196181
Br J Pharmacol. 2010 Jun;160(3):657-68
20590569
Pharmacotherapy. 2010 Jul;30(7):716-27
20575635
Free Radic Biol Med. 2006 Jul 15;41(2):202-12
16814100
Nat Rev Drug Discov. 2008 Sep;7(9):759-70
18758473
Hypertension. 2010 Jul;56(1):136-42
20530293
J Cell Mol Med. 2010 Jan;14(1-2):70-8
19968738
Toxicol Lett. 2010 May 19;195(1):68-74
20184945
Hypertension. 2010 Aug;56(2):297-303
20547972